deltatrials
Recruiting OBSERVATIONAL NCT05326620

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) (PRO-RCC)

PROspective Renal Cancer Cohort (PRO-RCC)

Sponsor: Bristol-Myers Squibb

Updated 8 times since 2022 Last updated: Jun 3, 2025 Started: Jan 19, 2023 Primary completion: Jan 31, 2030 Completion: Jan 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Renal Cancer and Renal Cell Cancer Metastatic and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2022 – ~Jun 2022 · 31 days · monthly snapshotNot Yet Recruiting~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshotNot Yet Recruiting~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotRecruiting~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotRecruiting~Sep 2025 – present · 10 months · monthly snapshotRecruiting

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Recruiting

  2. Jul 2025 — Sep 2025 [monthly]

    Recruiting

  3. Sep 2024 — Jul 2025 [monthly]

    Recruiting

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting

Show 3 earlier versions
  1. Feb 2023 — Feb 2024 [monthly]

    Recruiting

    Status: Not Yet RecruitingRecruiting

  2. Jun 2022 — Feb 2023 [monthly]

    Not Yet Recruiting

  3. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Comprehensive Cancer Centre The Netherlands
  • Ipsen
  • Merck Sharp & Dohme LLC
  • PROspective Renal Cancer Cohort Foundation
  • Pfizer
Data source: PROspective Renal Cancer Cohort Foundation

For direct contact, visit the study record on ClinicalTrials.gov .